I nvesting.com -- Veradigm shares plummeted 40% following the conclusion of a strategic review process that did not result in a sale or other deal. The healthcare data and technology solutions ...

Veradigm is ending its review of strategic alternatives for the company almost eight months after the process began. The healthcare technology company on Thursday said that while five bidders ...

Veradigm has insights as to how personalized and targeted messaging can drive awareness and engagement, ultimately improving the patient experience. Advancing Cardiac Care Through Health ...

Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, today announced the integration of two new datasets to expand the depth and breadth of Veradigm Network ...

CHICAGO--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that the Veradigm Board of Directors (the “Board ...

Shares of MDRX stock opened at $5.20 on Thursday. Veradigm has a 12 month low of $4.50 and a 12 month high of $11.80. The business’s 50 day moving average is $8.70 and its two-hundred day moving ...

Veradigm EHR is a robust platform that has grown with tens of thousands of providers nationwide for decades. With Veradigm’s easy navigation and telehealth integration, the company achieved a 9. ...

CHICAGO--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, today announced that on January 28, 2025, Beth Altman stepped down from the ...